REGENXBIO INC (RGNX)
Health Care · NASDAQ
RegenxBio Inc.
What REGENXBIO INC does
RegenxBio Inc. is a clinical-stage gene therapy company developing treatments for inherited retinal diseases, hemophilia B, and other genetic disorders. The company employs adeno-associated virus (AAV) vectors as its core technology platform to deliver therapeutic genes to target tissues. Key programs include collaborations with AbbVie for surabgene lomparvovec (ABBV-RGX-314) and with Nippon Shinyaku for RGX-121 and RGX-111, alongside an internal pipeline of investigational therapies in clinical and preclinical development.
Themes: ["Gene therapy / AAV-based treatments","Inherited retinal diseases","Lysosomal storage disorders","Hemophilia B","Genetic disorders / rare diseases"]
Fundamentals
- Price$15.65 as of 2026-07-09 close
- Market cap$793M as of 2026-07-10
- 1-year return+70.7% as of 2026-07-09 close
- Net margin-330.2% as of 2026-07-10
- Gross margin+68.2% as of 2026-07-10
- ROE-232.5% as of 2026-07-10
- Debt / equity8.41 as of 2026-07-10
- Revenue growth (YoY)-44.0% as of 2026-07-10
- Revenue CAGR (3y)+14.8% SEC XBRL
- Beta0.89 as of 2026-07-10
Key risks (from latest filing)
["Regulatory approval risk: Company faces a Complete Response Letter for RGX-121 and clinical holds for RGX-111 and RGX-121, requiring resolution with FDA before advancement","Dependence on development partnerships with AbbVie and Nippon Shinyaku; loss of these collaborations would significantly impact pipeline and commercialization prospects","Substantial cash burn and going concern: Company is unprofitable with negative net margin of -330.23% and declining revenue; requires additional financing to continue operations and fund clinical trials"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.